Multi Centre Study Comparing OsseoSpeed TX With OsseoSpeed
An Open, Randomized, Prospective Multi Centre Study Comparing OsseoSpeedTM TX With OsseoSpeedTM in the Partially and Totally Edentulous Maxillae
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Halmstad, Sweden
- Specialisttandvården, Hallands sjukhus
-
Jönköping, Sweden
- Avd. för Parodontologi / Avd. för Oral Protetik, Odontologiska Institutionen
-
Kalmar, Sweden
- Specialist- och sjukhustandvården
-
Linköping, Sweden, 581 85
- Centrum för Oral Rehablilitering
-
Mölndal, Sweden, 431 30
- Colossseumkliniken Mölndal
-
Stockholm, Sweden, 118 83
- Käkcentrum, Södersjukhuset
-
Stockholm, Sweden
- Specialisttandvården, S:t Eriks Sjukhus
-
Trollhättan, Sweden, 431 85
- Käkkirurgiska kliniken NÄL / Specialistcentrum Uddevalla sjukhus
-
Umeå, Sweden, 901 87
- Käkkirurgiska Kliniken/Protetikkliniken
-
Växjö, Sweden, 352 31
- Parodontologi kliniken och Protetik- och Bettfysiologiska kliniken
-
Örebro, Sweden, 701 85
- Käkkirurgiska kliniken / Protetikkliniken
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of informed consent
- Female/male aged 18 years and over
- History of edentulism in the study area of at least 3 months
- In need for implant(s) replacing missing tooth/teeth in the maxilla
- Deemed by the investigator to be suitable for one stage surgery
- Deemed by the investigator to be suitable for loading after 10-12 weeks
- Deemed by the investigator as likely to present an initially stable implant situation.
- Deemed by the investigator to have a "functional" opposing dentition at the time of loading the implants.
Exclusion criteria:
- Unlikely to be able to comply with study procedures, as judged by the investigator
- Uncontrolled pathological processes in the oral cavity
- Known or suspected current malignancy
- History of radiation therapy in the head and neck region
- History of chemotherapy within 5 years prior to surgery
- Systemic or local disease or condition that would compromise post-operative healing and/or osseointegration
- Uncontrolled diabetes mellitus
- Corticosteroids or any other medication that would compromise post-operative healing and/or osseointegration
- Present alcohol and/or drug abuse
- Current need for bone grafting and/or augmentation in the planned implant area
- Involvement in the planning and conduct of the study (applies to both Astra Tech staff and staff at the study site)
- Previous enrolment in the present study.
- Simultaneous participation in another clinical study, or participation in a clinical study during the last 6 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: B
|
OsseoSpeedTM implants of lengths 6-17 mm
|
|
Experimental: A
|
OsseoSpeedTM TX implants of lengths 6-17 mm
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Marginal Bone Level
Time Frame: One year after loading
|
Marginal Bone Level will be determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant.
Marginal Bone Level expressed in millimeters at the 12 months follow-up visit will be compared to values obtained at delivery of permanent restoration i.e. loading (baseline).
|
One year after loading
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implant stability
Time Frame: At implant placement (inclusion) (day 1)
|
Implant stability will be evaluated clinically/manually (recorded as stable yes/no)
|
At implant placement (inclusion) (day 1)
|
|
Implant stability
Time Frame: At implant placement (inclusion) (day 1)
|
Implant stability will be evaluated using Resonance Frequency Analysis (RFA)
|
At implant placement (inclusion) (day 1)
|
|
Implant stability
Time Frame: At implant loading (10-12 weeks after implant placement)
|
Implant stability will be evaluated clinically/manually (recorded as stable yes/no)
|
At implant loading (10-12 weeks after implant placement)
|
|
Implant survival
Time Frame: One year after loading
|
Implant survival rate will be evaluated by clinically and radiographically counting the number of remaining implants from implant placement to one year after loading.
|
One year after loading
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Carl-Johan Ivanoff, DDS, PhD, Colosseumkliniken Mölndal
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- YA-OTX-0001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.